Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308942 · ClinicalTrials.gov registry record · Phase 2
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
A Phase 2 study, sponsored by Tesaro.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03308942 is a Phase 2 study that has completed, run by Tesaro. The registered enrollment target is 53 participants.
The verdict
NCT03308942, a Phase 2 study, has completed, sponsored by Tesaro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of niraparib alone and in combination with PD-1 inhibitors in participants with locally advanced and metastatic non-small cell lung cancer (NSCLC). The study will consist of 2 stages. In stage 1, participants from Cohorts 1 and 2 will receive niraparib plus PD-1 inhibitor; pembrolizumab and participants from Cohort 3 will receive niraparib alone. In Stage 2, participants from Cohorts 1A and 2A will receive niraparib plus the PD-1 inhibitor, TSR-042 (Dostarlimab).
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Niraparib
- BIOLOGICAL TSR-042 (Dostarlimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03308942
The ClinicalTrials.gov registry entry for NCT03308942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03308942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03308942 about?
NCT03308942 is a clinical study titled "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants". This is a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of niraparib alone and in combination with PD-1 inhibitors in participants with locally advanced and metastatic non-small cell lung cancer (NSCLC). The study will consist of 2 stages. In stage 1, participants from C...
What is the current status of trial NCT03308942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-09-29. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT03308942?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Niraparib (DRUG), TSR-042 (Dostarlimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03308942?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.